A Phase I Dose-Escalation and Safety Study of BI 3821001 in Healthy Male Volunteers

The primary objective of this study is to evaluate the safety and tolerability of varying doses of BI 3821001 in healthy volunteers. Assessing dose tolerance is clinically significant for determining the safe administration range of the investigational product.

The sponsor did not provide information regarding the total number of participants. The study population consists of male healthy volunteers. The participants belong to an age category defined by code 3. No further data regarding lifestyle considerations, selection processes, or specific inclusion and exclusion criteria were provided.

This Phase 1 clinical trial is designed to evaluate the tolerability of varying doses of BI 3821001 in healthy volunteers. The research methodology follows a dose-escalation approach to assess safety parameters. The study sequence begins with a screening visit to determine eligibility. Following screening, participants undergo the intervention phase and subsequent follow-up visits to monitor physiological responses. The process concludes with an end-of-study visit. The total duration of participant involvement is determined by the specific study protocol. Early termination from the study may occur if predefined safety criteria or clinical conditions are met.

The primary objective of this Phase 1 clinical trial involves the assessment of safety and tolerability in healthy volunteers. Efficacy evaluation parameters are not defined for this study protocol.